journal
https://read.qxmd.com/read/37754204/ceftobiprole-for-treatment-of-complicated-staphylococcus-aureus-bacteremia
#1
JOURNAL ARTICLE
Thomas L Holland, Sara E Cosgrove, Sarah B Doernberg, Timothy C Jenkins, Nicholas A Turner, Helen W Boucher, Oleksander Pavlov, Ivan Titov, Serhii Kosulnykov, Boyko Atanasov, Ivan Poromanski, Manana Makhviladze, Anastasia Anderzhanova, Martin E Stryjewski, Maziar Assadi Gehr, Marc Engelhardt, Kamal Hamed, Daniel Ionescu, Mark Jones, Mikael Saulay, Jennifer Smart, Harald Seifert, Vance G Fowler
BACKGROUND: Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus bacteremia, including methicillin-resistant S. aureus . METHODS: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators)...
September 27, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37747040/swimming
#2
JOURNAL ARTICLE
Margaret Isaac
New England Journal of Medicine, Volume 389, Issue 13, Page 1164-1165, September 2023.
September 23, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37747039/herpes-simplex-dendritic-keratitis
#3
JOURNAL ARTICLE
Giuseppe Giannaccare, Massimiliano Borselli
New England Journal of Medicine, Volume 389, Issue 13, September 2023.
September 23, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37732608/a-holy-grail-the-prediction-of-protein-structure
#4
JOURNAL ARTICLE
Russ B Altman
No abstract text is available yet for this article.
September 21, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37732605/optical-coherence-tomography-and-eye-care
#5
JOURNAL ARTICLE
Cynthia A Toth
No abstract text is available yet for this article.
September 21, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37733295/from-ashes-to-action-indigenous-health-perspectives-on-the-l%C3%A4-hain%C3%A4-fires
#6
JOURNAL ARTICLE
Kekoa Taparra, Mālia Purdy, Kalani L Raphael
No abstract text is available yet for this article.
September 20, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37721384/the-ethics-of-abortion-care-advocacy-making-exceptions-to-the-rule
#7
JOURNAL ARTICLE
Beverly Gray, Jonas J Swartz
New England Journal of Medicine, Volume 389, Issue 12, Page 1064-1066, September 2023.
September 16, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37721382/the-new-uspstf-mammography-recommendations-a-dissenting-view
#8
JOURNAL ARTICLE
Steven Woloshin, Karsten Juhl Jørgensen, Shelley Hwang, H Gilbert Welch
New England Journal of Medicine, Volume 389, Issue 12, Page 1061-1064, September 2023.
September 16, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37721379/migrating-emboli-in-branch-retinal-artery-occlusion
#9
JOURNAL ARTICLE
Alexis Kassotis, Tarun Sharma
New England Journal of Medicine, Volume 389, Issue 12, September 2023.
September 16, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37721378/reducing-the-risks-of-nuclear-war-the-role-of-health-professionals
#10
JOURNAL ARTICLE
Kamran Abbasi, Parveen Ali, Virginia Barbour, Kirsten Bibbins-Domingo, Marcel G M Olde Rikkert, Andy Haines, Ira Helfand, Richard Horton, Bob Mash, Arun Mitra, Carlos Monteiro, Elena N Naumova, Eric J Rubin, Tilman Ruff, Peush Sahni, James Tumwine, Paul Yonga, Chris Zielinski
New England Journal of Medicine, Volume 389, Issue 12, Page 1066-1067, September 2023.
September 16, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37694893/threatening-the-global-aids-response-obstacles-to-pepfar-s-reauthorization
#11
JOURNAL ARTICLE
Salim S Abdool Karim, Francoise Barre-Sinoussi, Harold E Varmus, David Serwadda, Elizabeth Bukusi, Souleymane M'boup, Adeeba Kamarulzaman, Soumya Swaminathan, Jean W Pape
New England Journal of Medicine, Volume 389, Issue 13, Page 1159-1161, September 2023.
September 9, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37694885/a-doctrine-in-name-only-strengthening-prohibitions-against-the-corporate-practice-of-medicine
#12
JOURNAL ARTICLE
Jane M Zhu, Hayden Rooke-Ley, Erin Fuse Brown
New England Journal of Medicine, Volume 389, Issue 11, Page 965-968, September 2023.
September 9, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37694884/the-accelerated-approval-program-for-cancer-drugs-finding-the-right-balance
#13
JOURNAL ARTICLE
Bishal Gyawali, Aaron S Kesselheim, Joseph S Ross
New England Journal of Medicine, Volume 389, Issue 11, Page 968-971, September 2023.
September 9, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37672691/affirmative-action-population-health-and-the-importance-of-opportunity-and-hope
#14
JOURNAL ARTICLE
Atheendar S Venkataramani
New England Journal of Medicine, Volume 389, Issue 13, Page 1157-1159, September 2023.
September 6, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37668231/alleviating-medical-debt-in-the-united-states
#15
JOURNAL ARTICLE
Nishant Uppal, Steffie Woolhandler, David U Himmelstein
New England Journal of Medicine, Volume 389, Issue 10, Page 871-873, September 2023.
September 2, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37668225/mass-masking-without-mandates-the-role-of-gender-in-mask-use-in-china
#16
JOURNAL ARTICLE
Meng Zhang
New England Journal of Medicine, Volume 389, Issue 10, Page 874-875, September 2023.
September 2, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37646702/mezigdomide-plus-dexamethasone-in-relapsed-and-refractory-multiple-myeloma
#17
JOURNAL ARTICLE
Paul G Richardson, Suzanne Trudel, Rakesh Popat, María-Victoria Mateos, Annette J Vangsted, Karthik Ramasamy, Joaquín Martinez-Lopez, Hang Quach, Robert Z Orlowski, Mario Arnao, Sagar Lonial, Chatchada Karanes, Charlotte Pawlyn, Kihyun Kim, Albert Oriol, Jesus G Berdeja, Paula Rodríguez Otero, Ignacio Casas-Avilés, Alessia Spirli, Jennifer Poon, Shaoyi Li, Jing Gong, Lilly Wong, Manisha Lamba, Daniel W Pierce, Michael Amatangelo, Teresa Peluso, Paulo Maciag, Jessica Katz, Michael Pourdehnad, Nizar J Bahlis
BACKGROUND: Despite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. METHODS: In this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma. The primary objectives of phase 1 (dose-escalation cohort) were to assess safety and pharmacokinetics and to identify the dose and schedule for phase 2...
August 30, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37646699/mezigdomide-and-multiple-myeloma
#18
EDITORIAL
Jake Shortt
New England Journal of Medicine, Volume 389, Issue 11, Page 1046-1050, September 2023.
August 30, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37646697/preventing-heat-related-illness-among-outdoor-workers-opportunities-for-clinicians-and-policymakers
#19
JOURNAL ARTICLE
Rosemary K Sokas, Emily Senay
No abstract text is available yet for this article.
August 30, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37634190/timing-of-complete-revascularization-with-multivessel-pci-for-myocardial-infarction
#20
JOURNAL ARTICLE
Barbara E Stähli, Ferdinando Varbella, Axel Linke, Bettina Schwarz, Stephan B Felix, Moritz Seiffert, Rahel Kesterke, Peter Nordbeck, Bernhard Witzenbichler, Irene M Lang, Mirjam Kessler, Christian Valina, Alban Dibra, Miklos Rohla, Marco Moccetti, Matteo Vercellino, Luise Gaede, Lorenz Bott-Flügel, Philipp Jakob, Julia Stehli, Alessandro Candreva, Christian Templin, Matthias Schindler, Manfred Wischnewsky, Greca Zanda, Giorgio Quadri, Norman Mangner, Aurel Toma, Giulia Magnani, Peter Clemmensen, Thomas F Lüscher, Thomas Münzel, P Christian Schulze, Karl-Ludwig Laugwitz, Wolfgang Rottbauer, Kurt Huber, Franz-Josef Neumann, Steffen Schneider, Franz Weidinger, Stephan Achenbach, Gert Richardt, Adnan Kastrati, Ian Ford, Willibald Maier, Frank Ruschitzka
BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) with multivessel coronary artery disease, the time at which complete revascularization of nonculprit lesions should be performed remains unknown. METHODS: We performed an international, open-label, randomized, noninferiority trial at 37 sites in Europe. Patients in a hemodynamically stable condition who had STEMI and multivessel coronary artery disease were randomly assigned to undergo immediate multivessel percutaneous coronary intervention (PCI; immediate group) or PCI of the culprit lesion followed by staged multivessel PCI of nonculprit lesions within 19 to 45 days after the index procedure (staged group)...
August 27, 2023: New England Journal of Medicine
journal
journal
20199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.